Downregulation of proapoptotic molecules like Fas or caspase 8, or upregulation of antiapoptotic molecules like FLICE inhibitory protein has been suggested to be a regulatory mechanism set up by tumor cells to block the death signal received via death receptors. In an in-depth study of the Fas/FasL-signaling pathway in thyroid tumor development, we have demonstrated that tumor cells specifically downregulate the multideath receptor adapter Fas-associated death domain (FADD). The regulation of FADD expression occurred only at the protein level. Furthermore, in the absence of FADD, Fas-signaling resulted in accelerated growth of thyrocytes. Since thyrocytes also acquired FasL expression during tumor development, the absence of FADD protein could lead to greater resistance to numerous death receptor-mediated apoptosis, stimulation of their own proliferation through Fas/FasL interaction, and the capacity to counter-attack the infiltrating lymphocytes.
Introduction
Dysregulation of the Fas pathway is responsible for hypo-or hyperproliferative disorders that are as a result of excess or faulty apoptosis, respectively. FasL expression on tumor cells allows the cells to escape the immune system by killing infiltrating lymphocytes that express the receptor Fas, although this point is still controversial (Nagata, 1996; Strand et al., 1996; Favre-Felix et al., 2000; Restifo, 2000) . Usually, when tumor cells coexpress Fas and FasL molecules, they turn out to be resistant to Fas-mediated cell death. Among the regulatory mechanisms that may take place to block the death signal, downregulation of proapoptotic molecules such as Fas (Moller et al., 1994) or caspase 8 (Teitz et al., 2000) , or upregulation of antiapoptotic molecules such as FLIP (FLICE inhibitory protein) (Djerbi et al., 1999; Medema et al., 1999) has been reported during tumor progression.
Activation of Fas by its ligand leads to recruitment of the adapter molecule Fas-associated protein with death domain (FADD) , which, in turn, activates FLICE/ caspase 8, a process leading to apoptosis (Nagata, 1997) . FLIP, an antiapoptotic protein, can protect cells from apoptosis by preventing FADD-caspase 8 association (Irmler et al., 1997) . Fas death domain-associated protein (Daxx), a second adapter molecule, defines a different signaling pathway downstream of Fas (Yang et al., 1997) . It can independently activate both the Jun N-terminal kinases (JNK) and p38-mitogen-activated protein kinases (p38-MAPK) pathways through the apoptosis signal-regulating kinase 1 (ASK1) intermediate (Ichijo et al., 1997; Chang et al., 1998) . It seems that the JNK pathway generally leads to apoptosis, whereas p38 kinase can have pro-or antiapoptotic effects, the final result depending on multiple factors such as the type of cell and its state of differentiation. Recently, the kinase receptor-interacting protein (RIP) was reported to be a third adapter for Fas (Holler et al., 2000) . It can transduce Fas-mediated caspase-dependent or -independent cell death.
The thyroid is of particular interest regarding the role of Fas/FasL since Fas is constitutively expressed by normal thyroid follicular cells (TFC), and FasL expression can occur in numerous pathological thyroid conditions (Baker, 1999) , including cancer (Mitsiades et al., 1999 ), Hashimoto's thyroiditis (Giordano et al., 1997 ) and Grave's disease (Hiromatsu et al., 1999) .
In the thyroid gland, guanine nucleotide stimulatory factor (Gs) activates adenylate cyclase in response to thyrotropin stimulation, leading to cyclic AMP level elevation and subsequent thyroid cell proliferation (Dumont et al., 1992) . Mutations of the a subunit of the Gs factor (gsp mutations), resulting in constitutive activation of adenylate cyclase, are found in approximately 30% of human thyroid toxic adenomas and 10% of human thyroid carcinomas (Suarez et al., 1991; Said et al., 1994) . Transgenic mice expressing a mutant form of the Gsa subunit directed to TFC (gsp mice) have turned out to be a powerful model for studying human thyroid tumors. These mice have inherited with the gsp transgene a highly penetrant predisposition to develop thyroid hyperplasia that eventually transforms into hyperfunctioning thyroid adenomas at the age of 8 months (Michiels et al., 1994) . Interestingly, adenocarcinomas of the thyroid have been observed in the progeny of animal breed of a specific genetic background, suggesting that the gsp-linked phenotype is sensitive to the genetic modifiers (F-M Michiels, unpublished observations).
We investigated the presence of a wide array of signaling molecules of the Fas cascade in these mice. Our results show that FasL expression was acquired during tumor development, with a stronger expression in adenoma/adenocarcinoma (AAC) than in hyperplasia, but not in normal thyroid cells. Among the adapters for Fas, only FADD was regulated, in that FADD protein expression was weak or completely lost in AAC, although FADD mRNA was present. Furthermore, in an in vitro model of thyrocytes culture, the absence of FADD resulted in a Fas signaling leading to faster growth of the thyrocytes.
Results

Fas ligand expression is acquired during tumor development
Since FasL expression has been reported in human thyroid carcinoma, we studied the presence of this molecule in mouse thyroid AAC. We analysed thyroids at various stages of tumor development by semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR) and Western blot. Neither FasL mRNA norFasL protein could be detected in normal thyroid tissue from NTG mice (not shown). In nonpathological (NP) thyroid glands from gsp mice, FasL mRNA and protein were absent in all mice tested (Figure 1a , b, respectively), whereas they could be detected in hyperplastic (HP) thyroids, and at higher levels in thyroid AAC ( Figure  1a, b) . Moreover, we detected both the membranebound (40 kDa) and soluble (26 kDa) forms of FasL in AAC. By contrast, RT-PCR and Western blot analysis showed that Fas mRNA and protein were expressed both in NP and pathological thyroids (Figure 1a, b) .
FADD protein, but not Daxx and RIP, is lost during tumor development
Since Fas is known to act through the recruitment of adapter molecules, we first investigated the modulation of FADD, Daxx and RIP (Figure 2 ). mRNAs of these Fas adapters were detectable in thyroids from NTG and transgenic mice, and their respective levels of expression of mRNAs were increased during the course of tumor development, with a maximal expression observed in AAC (Figure 2a, b) . Western blot analysis showed that high levels of FADD protein were detected in all NP (3/3) and HP (4/4) glands from gsp mice. Interestingly, (Figure 2d ). Although we observed an interindividual heterogeneity, the overall expression of RIP protein was only slightly increased in AAC compared to NP thyroid gland (Figure 2d ).
Biased Fas-signaling pathway in the absence of FADD
The above results show that both Daxx and RIP, but not or few FADD, proteins were expressed in thyroid AAC. The next step was to study the downstream effector proteins of these signaling pathways. Western blot analysis of ASK1 protein, the intermediate between Daxx and kinase pathways, showed that ASK1 expression strongly increased during tumor growth (Figure 3a) , whereas the level of expression of HSP27, an inhibitor of the Daxx/ASK1 interaction, was unchanged ( Figure 3b ). On the other hand, RIP kinase can induce apoptosis because of caspase 2 activation. Western blot analysis showed that procaspase 2 long (48 kDa), a proapoptotic form of caspase 2, was always expressed in thyroids, regardless of the tumoral status of the gland. By contrast, both antiapoptotic forms of caspase 2 (procaspase 2 short (35 kDa) (Droin et al., 2001 ) and/or caspase 2 long prodomain (15 kDa) (Droin et al., 2000) ) were only expressed in tumoral specimens. Although the 35 kDa form was barely expressed in AAC, high levels of the 15 kDa form were detected (Table 1) . These results suggest that the RIP-caspase 2 pathway was not the main Fas-signaling pathway during tumor development. Thus, in the absence of FADD, Fas signaling seems to act mainly through a Daxx-ASK1 pathway.
Inhibition of the kinase pathway during tumor development
We further investigated the two main kinase-signaling pathways downstream of ASK1. We detected MKK3/MKK6-phosphorylated active proteins in gsp thyroids regardless of the tumoral status of the gland (Figure 3c ). Since total MKK3 was strongly The average expression of total p38-MAPK, the kinase downstream of MKK3/MKK6, was increased in HP and AAC glands ( Figure 4a ). By contrast, expression of the p38-phosphorylated active form was strongly decreased during tumor development (Figure 4b ). High levels of thr180/tyr182 phospho-p38-MAPK protein were detected in all NP thyroids, whereas its expression was low in HP glands, and very weak or absent in AAC. A decrease or absence of p38-MAPK activation correlated with a decrease or absence of total MKK3 expression (Figures 3c and 4b) .
The other kinases activated by ASK1 are SEK1/ MKK4 and SAPK/JNK molecules. We detected higher levels of total SEK1 protein in AAC than in NP and HP glands. Nevertheless, the levels of thr261 phospho-SEK1 Although the total and phospho-SAPK/JNK protein levels were similar in all groups of mice, the apparent molecular weight of phosphorylated proteins was higher in NP thyroids compared to diseased glands (Figure 3e ). These results suggest that SAPK/JNK proteins are phosphorylated at both thr183 and tyr185 sites in NP thyroids, but that HP glands and AAC are monophosphorylated because of the lack of phospho-SEK1-dependent thr183 phosphorylation. Since dual phosphorylation of SAPK/JNK is necessary for kinase activity, the ASK1/SEK1/JNK pathway, as the ASK1/ MKK3/p38-MAPK-signaling pathway, is inhibited during tumor development.
In vitro cultured thyrocytes do not express FADD protein
In the course of our study, we investigated the presence of molecules of the Fas-signaling pathway in in vitro cultures of NTG thyrocytes. Although FADD mRNA was expressed (Figure 5a ), FADD protein was undetectable ( Figure 5b ). Loss of FADD protein expression was induced shortly after dissociation of thyroid tissue with collagenase H (Figure 5b ), and FADD protein could not be detected up to 10 days of culture (not shown). From these results, it was important to find out whether loss of FADD protein was an intrinsic property of cultured TFC or a generalized FADD protein expression regulation mechanism. We chose hepatocytes to compare with thyrocytes because both are epithelial cells, and liver tissue requires collagenase H treatment before culture. Both ex vivo tissues expressed FADD protein (Figure 5b ). Western blotting of collagenase Htreated and in vitro-cultured hepatocytes showed the presence of FADD protein (Figure 5c ). These results suggest that loss of FADD protein expression was restricted to TFC, and that this in vitro culture system could be used to elucidate the consequences of FADD protein expression regulation by thyrocytes.
Fas signaling in the absence of FADD increases TFC growth
To evaluate the biological consequences of the Fas/FasL interaction in the absence of FADD protein, we cultured TFC with or without anti-Fas antibody and determined [ 3 H]thymidine incorporation of thyrocytes every day Proteasome inhibitors did not induce FADD protein expression on cultured TFC
As mRNA for FADD but not protein was expressed by cultured thyrocytes, an explanation could be that FADD protein was degraded after synthesis. Subconfluent thyroid epithelial cells cultures were treated with proteasome inhibitors, including proteasome inhibitor I (PI-I), lactacystin and MG132, alone or combined, and FADD expression was tested by Western blot analysis. None of these inhibitors, even at high dose or associated, was able to induce FADD protein expression in TFC cultures (Figure 7 ), whereas Daxx protein expression was highly increased after treatment of TFC by combining PI-I and lactacystin or lactacystin and MG132 ( Figure 7 ).
Discussion
In mice, transgenic expression of a mutant form of the Gsa subunit directed to TFC induces adenomas or adenocarcinomas. We focused on Fas/FasL-and Fas-
In vitro cultured thyrocytes 695 bp
Ex vivo liver a b 
kDa E x v iv o li v e r E x v iv o t h y r o id C o ll a g e n a s e H t r e a t e d t h y r o id I n v it r o c u lt u r e d t h y r o c y t e s c kDa E x v iv o li v e r C o ll a g e n a s e H t r e a t e d li v e r I n v it r o c u lt u r e d h e p a t o c y t e s
E x v iv o li v e r E x v iv o te s t is
In vitro cultured thyrocytes et al., 1996) , and by stimulating their own proliferation (Desbarats and Newell, 2000) . However, the regulatory mechanisms that occur in such a context are poorly understood. We focused on the expression of a large array of molecules involved in the Fas/FasL pathway during the in vivo transformation process of murine TFC. We showed that during this process: (1) FasL expression is gained; (2) FADD protein, but not mRNA, is lost; (3) Fas signaling in the absence of FADD results in a Daxxmediated signal; (4) the inactivated status of the p38-MAPK is correlated with an MKK3 decrease and absence of FADD protein expression; and (5) Fas signaling, in the absence of FADD, accelerated TFC growth. This is the first instance in which spontaneous FADD protein disappearance has been associated with any pathological consequence.
Inhibition of FADD function by gene targeting or by expression of dominant-negative interfering mutant has been described on T lymphocytes, and was shown to render T-cells resistant to apoptosis induced by Fas (Newton et al., 1998; Zhang et al., 1998) . In these models, FADD defects also resulted in an inhibition of mitogen-induced T-cell proliferation, demonstrating that FADD can transmit both apoptotic and growth and/or survival signals. Conversely, it was found that FADD deficiency in rag-1 À/À mice induced the development of thymic lymphoma, indicating that FADD can also act as a tumor suppressor (Newton et al., 2000) . These results demonstrate that FADD protein could have various effects, depending on the time of its expression, the tissue and the developmental status of the tissue. In our model, we showed that FADD protein might have a tumor suppressive function. Indeed, Fas signaling in TFC, in the absence of FADD, promotes cell growth. These results were confirmed by the higher proliferative rate of FADD-negative TFC expressing FasL, isolated from thyroid-specific FasL transgenic mice, compared to NTG thyrocytes (not shown).
In T lymphocytes, Fas ligation can result either in apoptosis or in proliferation depending on previous antigenic stimulation (Desbarats et al., 1999) . In human dermal fibroblasts, although anti-Fas antibody stimulates proliferation of low-Fas-expressing cells, anti-Fas treatment triggers apoptosis of high-Fas-expressing fibroblasts (Freiberg et al., 1997) . More surprisingly, in liver, Fas engagement can accelerate organ regeneration after partial hepatectomy, instead of inducing fulminant hepatitis (Desbarats and Newell, 2000) . These data demonstrate that signaling through Fas can result either in apoptosis or in proliferation, depending on the type of cell and the environmental conditions. In tumor cells, anti-Fas-promoted cell growth has been reported, and involved hematological as well as nonhematological tumors (Owen-Schaub et al., 1993) .
FADD is a signaling molecule common to numerous death receptors. Stimulation of tumor necrosis factor (TNF) receptor 1 (TNFR1) with TNF leads to recruitment of TNFR-associated death domain (TRADD), which can, in turn, bind FADD and TNFR-associated factor 2 (TRAF2). As FADD protein is not expressed in thyroid AAC, TNF stimulation would result only in a TRAF2-dependent transducing signal. Furthermore, FADD-deficient embryonic fibroblasts were shown to be resistant to apoptosis induced by TNFR1 (Yeh et al., 1998) , suggesting that FADD is essential to TNFmediated cell death. We found that FADD-deficient TFC were resistant to TNFa-mediated cell death (not shown), supporting the idea that tumoral TFC also acquire resistance to TNFR1-induced apoptosis. FADD is also necessary for death receptor 3 (DR3)-induced apoptosis (Yeh et al., 1998) . The requirement of FADD for TNF-related apoptosis-inducing ligand (TRAIL)-mediated cell death of tumor cells through two death receptors, DR4 and DR5, was also demonstrated (Kuang et al., 2000) . All these data show that apoptosis induced by Fas, TNFR1, DR3, DR4 and DR5 needs the FADD molecule, implying that all these death pathways might be blocked in the absence of FADD. Interestingly, human primary thyrocytes, as well as the KAT5 human papillary thyroid carcinoma-derived cell line, were shown to express DR4 and DR5, but to resist TRAIL-induced apoptosis (Bretz et al., 1999) . Thus, FADD deficiency would confer on tumor cells multiple resistance against death receptor-induced apoptosis.
But what are the molecular mechanisms that regulate expression of FADD protein?
One classical mechanism for the cells to degrade a protein is the targeting to the proteasome. However, we found that none of the proteasome inhibitors we tested was able to restore FADD protein expression.
In eucaryotic cells, translation of mRNAs is mainly because of a cap-dependent mechanism through m 7 GpppN cap structure recognition (Gingras et al., 1999) . On the other hand, some mRNAs are translated by a cap-independent mechanism. In this case, ribosome entry occurs at a specific region in the 5 0 end of mRNA called the internal ribosome entry segment (IRES). Few mRNAs possessing IRES have been described in mammalians and, to our knowledge, all are implicated in the control of cell growth (Vagner et al., 1995; Bernstein et al., 1997; Miller et al., 1998) . For instance, c-myc mRNA can be translated by both cap-dependent and -independent mechanisms. It has been demonstrated that the p38-MAPK-signaling pathway is implicated in this cap-independent translation (Stoneley et al., 2000) . Interestingly, no cap site was found in FADD mRNA (Kim et al., 1996) , and the phospho-p38-MAPK pattern of expression was very similar to that of FADD (Figures 2c and 4b) . Thus, FADD mRNA regulation of cap-independent translation could occur via the p38-MAPK pathway.
Our data suggest a new role for the Fas/FasL pathway in the etiology of thyroid tumor. In the absence of FADD protein, but in the presence of Fas and FasL molecules, thyrocytes would have numerous advantages: high resistance to Fas and other death receptormediated apoptosis; stimulation of their own proliferation through Fas/FasL interaction ( Figure 8) ; and the capacity to counter-attack the infiltrating lymphocytes, allowing immune escape (Batteux et al., 2000; Tourneur et al., 2001) . Understanding how FADD protein expression is lost will enable us to envisage new therapeutic approaches. Restoration of FADD function in FasL + thyrocytes would induce greater Fas-mediated cell death susceptibility, and inhibit Fas-induced proliferation of these cells, leading to tumor regression. Moreover, our results could probably be extended to many types of cancer.
Materials and methods
Mice
Gsp transgenic mice have been described elsewhere (Michiels et al., 1994) . CBA/J female mice (Iffa Credo, L'Arbresle, France) were used at 8-10 weeks of age. All mice were maintained in standard environmental conditions, and allowed to adapt to their environment for 1 week before the experiments. Thyroid tumor development was monitored by measurement of T 4 and T 3 serum levels.
Reagent PI-I, lactacystin and MG132 were purchased from Calbiochem (Calbiochem-Novabiochem Corp., La Jolla, CA, USA).
Semiquantitative RT-PCR
Thyroids of gsp mice were collected at various stages of tumor development and RNA was isolated from cells using 500 ml to 1 ml Tri-Reagent per thyroid (Molecular Research Center, Cincinnati, Ohio, USA). For the in vitro culture model, TFC were cultured in 24-well, flat-bottomed plates (model 3524, Costar, Cambridge, MA, USA). At subconfluence, TFC cultures were washed, and RNA was isolated using 250 ml/well Tri-Reagent. Contaminating DNA was eliminated by DNAse (Ozyme, Saint Quentin Yvelines, France) treatment. Reverse transcription was performed on 1-2 mg total RNA using Superscript II reverse transcriptase (Life Technologies, Inc., Cergy Pontoise, France). cDNA (50 ng) was amplified by PCR using 0.5 U Taq polymerase (Life Technologies) and specific primers: FasL (425 bp 0 , antisense 5 0 -TAAAACGCAGCTCAGTAACAGTCCG-3 0 ) was used as control. For quantification, serial, twofold dilutions of cDNA were amplified for 25 cycles using b-Actin primers. cDNA giving equivalent amount of b-Actin were then amplified for 24-30 PCR cycles. The RT-PCR products were subjected to electrophoresis on a 2% agarose gel and stained with ethidium bromide. Amplified fragments were quantified by densitometry using biocapt s and bio-profil bio1d s softwares. 
Western blot
Thyroids of gsp mice were collected at various stages of tumor development, and total proteins were extracted with lysis buffer (10 mm Tris-HCl, 150 mm NaCl pH 7.8, 1% NP40, 1 mm PMSF, 1 mg/ml aprotinin and 1 mg/ml leupeptin), containing a cocktail of protein phosphatase inhibitors (CalbiochemNovabiochem Corp.). TFC were cultured in vitro in six-well, flat-bottomed plates (model 3516, Costar). At subconfluence, TFC were washed and total proteins were extracted. Sample concentrations were determined using a micro-BCA protein assay reagent kit (Pierce, Rockford, IL, USA), and 25 mg of total proteins was subjected to SDS-PAGE and transferred to nitrocellulose (NEN Life Sciences, Boston, MA, USA 
Culture of primary thyrocytes
Thyroid tissue was obtained from control CBA/J female mice. Animals were killed and the two thyroid lobes removed after intracardiac puncture. The collected lobes were digested in 1.5 mg/ml collagenase H (Boehringer Mannheim, Mannheim, Germany) solution for 45 min at 371C. TFC were then cultured at 371C in a 5% CO 2 atmosphere, in RPMI 1640 medium supplemented with 5% fetal bovine serum, 1% penicillinstreptomycin solution and 5 Â 10 À5 m 2-mercaptoethanol.
Nonadherent cells were removed by washing to obtain TFC pure cultures. Cells reached subconfluence after 5-6 days of culture.
Culture of primary hepatocytes
BALB/c hepatocytes were prepared according to Mazier et al. (1985) with minor modifications. Briefly, cells were isolated by perfusion of the liver fragments with collagenase (Boehringer, Mannheim, Germany), following purification in a 60% Percoll gradient (Pharmacia Biotech, Uppsala, Sweden). Purified hepatocytes showed at least 95% viability and purity as assessed by Trypan blue dye exclusion. They were cultured in William's E medium (Gibco, Irvine, UK) supplemented with 5% fetal calf serum and 1% penicillin-streptomycin solution following incubation at 371C for 24 h in a 3.5% CO 2 atmosphere.
Proliferation assay
TFC were cultured in 96-well, flat-bottomed plates (model 3599, Costar) at approximately 18 000 cells/well in the absence or presence of clone Jo2 anti-Fas antibody (0.5 mg/ml, PharMingen) and in the absence or presence of polyclonal control Ig (0.5 mg/ml, PharMingen). Proliferation of thyrocytes was determined from 24 to 120 h. Thyrocytes were pulsed with 0.5 mCi of 
